| Literature DB >> 15970168 |
José M Miró1, Julián Torre-Cisnero, Asunción Moreno, Montserrat Tuset, Carmen Quereda, Montserrat Laguno, Elisa Vidal, Antonio Rivero, Juan Gonzalez, Carlos Lumbreras, José A Iribarren, Jesús Fortún, Antonio Rimola, Antonio Rafecas, Guillermina Barril, Marisa Crespo, Joan Colom, Jordi Vilardell, José A Salvador, Rosa Polo, Gregorio Garrido, Lourdes Chamorro, Blanca Miranda.
Abstract
Solid organ transplant may be the only therapeutic alternative in some HIV-infected patients. Experience in North America and Europe during the last five years shows that survival at three years after an organ transplant is similar to that observed in HIV-negative patients. The criteria agreed upon to select HIV patients for transplant are: no opportunistic infections (except tuberculosis, oesophageal candidiasis or P. jiroveci -previously carinii- pneumonia), CD4 lymphocyte count above 200 cells/.L (100 cells/.L in the case of liver transplant) and an HIV viral load which is undetectable or suppressible with antiretroviral therapy. Another criterion is a two-year abstinence from heroin and cocaine, although the patient may be in a methadone programme. The main problems in the post-transplant period are pharmacokinetic and pharmacodynamic interactions between antiretorivirals and immunosuppressors, rejection and the management of relapse of HCV infection, which is one of the main causes of post-liver transplant mortality. Up to now, experience with pegylated interferon and ribavirin is scarce in this population. The English version of the manuscript is available at http://www.gesidaseimc.com.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15970168 DOI: 10.1157/13076175
Source DB: PubMed Journal: Enferm Infecc Microbiol Clin ISSN: 0213-005X Impact factor: 1.731